IGC PHARMA INC (IGC)
US45408X3089 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 400K -55.56% | 910K 127.50% | 1.345M 47.80% | 1.142M -15.09% | 1.297M 13.57% | 1.515M 16.81% | |
| EBITDA YoY % growth | -10.03M -21.72% | -10.53M -4.99% | -8.161M 22.50% | N/A | N/A | N/A | |
| EBIT YoY % growth | -10.68M -22.48% | -11.19M -4.78% | -8.798M 21.38% | -9.962M -13.23% | -10.746M -7.87% | -12.802M -19.13% | |
| Operating Margin | -2,670.00% | -1,229.67% | -654.13% | -872.34% | -828.52% | -845.00% | |
| EPS YoY % growth | N/A | N/A | N/A | -0.11 50.52% | -0.10 4.59% | -0.12 -15.54% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.03 | -0.03 93.44% | -0.02 22.43% | -0.02 -16.35% | -0.02 11.28% | -0.02 11.28% |
| Revenue Q2Q % growth | 254.52K 24.76% | 300.475K 1.86% | 301.99K 11.03% | 323.2K -21.55% | 226.24K -11.11% | 328.25K 9.24% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.578M -14.30% | -2.55M -33.08% | -2.343M 1.13% | -2.331M -30.67% | -2.389M 7.33% | -2.331M 8.58% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.02 | -0.03 | 0.01 | 23.75% |
| Q1 2025 Q2Q % growth | -0.03 | -0.03 | 0.00 | -14.37% |
| Q4 2024 Q2Q % growth | -0.40 | -0.04 | -0.36 | -890.10% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 412K 42.07% | 298.455K | 113.545K | 38.04% |
| Q1 2025 Q2Q % growth | 272K -51.43% | 460.055K | -188.055K | -40.88% |
| Q4 2024 Q2Q % growth | 295K 73.53% | 194.93K | 100.07K | 51.34% |
| Q3 2024 Q2Q % growth | 204K -38.18% | % | ||
| Q2 2024 Q2Q % growth | 290K 45.00% | % | ||
| Q1 2024 Q2Q % growth | 560K 166.67% | % | ||
| Q4 2023 Q2Q % growth | 170K 41.67% | % | ||
| Q3 2023 Q2Q % growth | 330K 135.71% | % | ||
| Q2 2023 Q2Q % growth | 200K 233.33% | % | ||
| Q1 2023 Q2Q % growth | 210K 162.50% | % | ||
| Q4 2022 Q2Q % growth | 120K 50.00% | % | ||
| Q3 2022 Q2Q % growth | 140K 27.27% | % | ||
| Q2 2022 Q2Q % growth | 60K -53.85% | % | ||
| Q1 2022 Q2Q % growth | 80K -86.21% | % | ||
| Q4 2021 Q2Q % growth | 80K 166.67% | % | ||
| Q3 2021 Q2Q % growth | 110K -80.70% | % | ||
| Q2 2021 Q2Q % growth | 130K -92.86% | % | ||
| Q1 2021 Q2Q % growth | 580K -64.85% | % | ||
| Q4 2020 Q2Q % growth | 30K -98.05% | % | ||
| Q3 2020 Q2Q % growth | 570K -55.81% | % | ||
| Q2 2020 Q2Q % growth | 1.82M 124.69% | % | ||
| Q1 2020 Q2Q % growth | 1.65M 11.49% | % | ||
| Q4 2019 Q2Q % growth | 1.54M 35.09% | % | ||
| Q3 2019 Q2Q % growth | 1.29M 69.74% | % | ||
| Q2 2019 Q2Q % growth | 810K 237.50% | % | ||
| Q1 2019 Q2Q % growth | 1.48M 2,860.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 35.08% | 0% | -4.81% |
| Revenue | 0% | 9.09% | 0% | -15.59% |